Evidence map›Paper›PMID 32611757›Full record

ArticleJournal of virology2020

Dimerization of Dengue Virus E Subunits Impacts Antibody Function and Domain Focus.

Ashlie Thomas, Devina J Thiono, Stephan T Kudlacek, John Forsberg, Lakshmanane Premkumar, Shaomin Tian, Brian Kuhlman, Aravinda M de Silva, Stefan W Metz

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine.Frontiers in cellular and infection microbiology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Ashlie ThomasDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, USA.
Devina J ThionoDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, USA.
Stephan T KudlacekDepartment of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, North Carolina, USA.
John ForsbergDepartment of Pharmacology, University of North Carolina, Chapel Hill, North Carolina, USA.
Lakshmanane PremkumarDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, USA.
Shaomin TianDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, USA.
Brian KuhlmanDepartment of Biochemistry and Biophysics, University of North Carolina, Chapel Hill, North Carolina, USA.
Aravinda M de SilvaDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, USA.
Stefan W MetzDepartment of Microbiology and Immunology, University of North Carolina, Chapel Hill, North Carolina, USA swmetz@med.unc.edu.ORCID 0000-0002-9249-2844
University of North Carolina at Chapel Hill · US

Funding

Virology Research Program (Program 4)P30CA016086 · NCI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Deborah F. Tate · 1985 to 2026
$201.5M
Protein Expression/Dengue Virology CoreU19AI109784 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI TING, JENNY P · 2014 to 2018
$20.8M
UNC Initiative for Maximizing Student DevelopmentR25GM055336 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI COOK, JEANETTE GOWEN, KASH, THOMAS L. · 1996 to 2023
$12.1M
GPU workstation for deep learning-based protein design and cryo-EM data processingR35GM131923 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI BRIAN A KUHLMAN · 2019 to 2026
$6.1M
Molecular Basis of Flavivirus Cross-Neutralization by Human AntibodiesR01AI107731 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DESILVA, ARAVINDA M. · 2013 to 2022
$5.3M
MOLECULAR AND CELLULAR BIOPHYSICS TRAINING PROGRAMT32GM008570 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI KUHLMAN, BRIAN A, SLEP, KEVIN C · 1995 to 2022
$5.1M
NCI NIH HHS P30 CA016086NIAID NIH HHS R01 AI107731NIAID NIH HHS U19 AI109784NIGMS NIH HHS R35 GM131923NIGMS NIH HHS T32 GM008570
6 · The paper itself

Abstract

Dengue virus (DENV) is responsible for the most prevalent and significant arthropod-borne viral infection of humans. The leading DENV vaccines are based on tetravalent live-attenuated virus platforms. In practice, it has been challenging to induce balanced and effective responses to each of the four DENV serotypes because of differences in the replication efficiency and immunogenicity of individual vaccine components. Unlike live vaccines, tetravalent DENV envelope (E) protein subunit vaccines are likely to stimulate balanced immune responses, because immunogenicity is replication independent. However, E protein subunit vaccines have historically performed poorly, in part because the antigens utilized were mainly monomers that did not display quaternary-structure epitopes found on E dimers and higher-order structures that form the viral envelope. In this study, we compared the immunogenicity of DENV2 E homodimers and DENV2 E monomers. The stabilized DENV2 homodimers, but not monomers, were efficiently recognized by virus-specific and flavivirus cross-reactive potently neutralizing antibodies that have been mapped to quaternary-structure epitopes displayed on the viral surface. In mice, the dimers stimulated 3-fold-higher levels of virus-specific neutralizing IgG that recognized epitopes different from those recognized by lower-level neutralizing antibodies induced by monomers. The dimer induced a stronger E domain I (EDI)- and EDII-targeted response, while the monomer antigens stimulated an EDIII epitope response and induced fusion loop epitope antibodies that are known to facilitate antibody-dependent enhancement (ADE). This study shows that DENV E subunit antigens that have been designed to mimic the structural organization of the viral surface are better vaccine antigens than E protein monomers.

Indexed as

AnimalsAntibodies, MonoclonalAntibodies, ViralAntibody-Dependent EnhancementChlorocebus aethiopsCross ReactionsDengueDengue VaccinesDengue VirusDisease Models, AnimalEpitopesFemaleHEK293 CellsHumansImmunogenicity, VaccineMiceAntibodies, MonoclonalAntibodies, ViralDengue VaccinesEpitopesE protein TH Sman, Dengue virusProtein IsoformsVaccines, SubunitViral Envelope Proteinsantibody focusdengue virusenvelope proteinhomodimersneutralizing antibodiessubunit vaccine

Identifiers

PMID32611757
PMCPMC7459570
OpenAlexW3040101654

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.